network member

Missouri

About Network Member

Currently Enrolling

HCRN-BRE21-516

BRIDGET: Secondary BRain metastases prevention after Isolated intracranial progression on Trastuzumab/Pertuzumab or T-DM1 in patients with aDvanced human epidermal Growth factor receptor 2+ brEast cancer with the addition of Tucatinib

Cancer areas:Breast

Dana-Farber Cancer Institute

Duke Cancer Institute

MD Anderson Cancer Center

Novant Health Oncology Specialists

Providence Cancer Institute

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

The Ohio State University

UC San Francisco

University of Michigan Rogel Cancer Center

See clinicaltrials.gov

Currently Enrolling

HCRN-GU16-243

PhAse I/II StuDy of Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the BLADDER – (ADAPT-BLADDER) HCRN GU16-243

Noah M. Hahn

Cancer areas:Bladder Urothelial Carcinoma

Columbia University Irving Medical Center

Fox Chase Cancer Center

Fred & Pamela Buffett Cancer Center

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

University of Iowa Holden Comprehensive Cancer Center

See clinicaltrials.gov

Enrollment Closed

HCRN-GU18-343

A Phase 2 Study of CAbozantinib in Combination With AtezolizumaB as NeoAdjuvant Treatment for Muscle-Invasive BladdEr Cancer (ABATE)

Deepak Kilari

Cancer areas:Bladder

Froedtert & the Medical College of Wisconsin

John Theurer Cancer Center at Hackensack Meridian Health

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

University of Rochester Medical Center - Wilmot Cancer Institute

Vanderbilt-Ingram Cancer Center

Virginia Commonwealth University

See clinicaltrials.gov

Study Completed

HCRN-BRE20-442

Phase II Study of The Combination of Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

See clinicaltrials.gov

Enrollment Closed

HCRN-MEL17-309

Phase II single-arm multi-center study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma

Suthee Rapisuwon

Cancer areas:Melanoma

Columbia University Irving Medical Center

Georgetown Lombardi Comprehensive Cancer Center

MD Anderson Cancer Center

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

UC San Francisco

See clinicaltrials.gov